Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karen Garby

Vascular & Interventional Radiology Mesa, AZ Medical Doctor

NPI 1306835020 CMS profile 285787

1457 W Southern Ave, Suite 26, Mesa, AZ 85202

Open in the dashboard

General payments

$5,551

217 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karen Garby of Mesa, AZ is reported in the CMS Open Payments database as having received $5,551 across 217 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $500 15
2024 General $615 16
2023 General $1,083 31
2022 General $1,687 51
2021 General $450 22
2020 General $393 31
2019 General $823 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Garby
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Karen Garby were reported at $500. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Karen Garby Vascular & Interventional Radiology median Middle half National median
2019 $823 $422 $125–$1,555 $163
2020 $393 $200 $68–$652 $114
2021 $450 $280 $99–$866 $132
2022 $1,687 $433 $137–$1,497 $149
2023 $1,083 $506 $152–$2,019 $160
2024 $615 $556 $175–$1,930 $164
2025 $500 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $1,114 7 payments
  2. Siemens Medical Solutions USA, Inc. $1,008 10 payments
  3. Tactile Systems Technology Inc $859 86 payments
  4. Medtronic, Inc. $586 43 payments
  5. Boston Scientific Corporation $511 18 payments
  6. AngioDynamics, Inc. $479 35 payments
  7. Koya Medical, Inc. $434 2 payments
  8. Medtronic Vascular, Inc. $159 2 payments
  9. Biosense Webster, Inc. $155 1 payment
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $37 2 payments
  11. Other $209 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,659 216 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $892 1 payment
Products named General payments · program years 2019–2025
  1. Omnia $1,120 7 payments
  2. ACUSON Sequoia Diagnostic Ultrasound System $521 5 payments
  3. ENTRE $453 70 payments
  4. ACTITOUCH $453 70 payments
  5. FLEXITOUCH $453 70 payments
  6. Flexitouch Plus $405 16 payments
  7. AURYON LASER SYSTEM 100-120 VAC $374 33 payments
  8. Entre Plus $372 14 payments
  9. Dayspring $367 1 payment
  10. Sequoia $345 3 payments
  11. Other $2,321 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

49

Median for Diagnostic Radiology: 24

Drug cost

$40,988

Median for Diagnostic Radiology: $190

Branded share of claims

77.6%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 38 $40,755
Pentoxifylline Generic 11 $233

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$469,907

Medicare's payments for the services billed

Medicare patients

1,214

Average age 76

Services billed

3,216

682 women, 532 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 55%
Chronic kidney disease 39%
Ischemic heart disease 36%
Heart failure 21%
Atrial fibrillation 21%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

217 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record